Assessment of Incidence and Character of Neurologic/ Neuropsychiatric Complications in a Group of Patients with Malignant Melanoma Treated with Adjuvant High Dose Interferon

Česká verzia

Authors: Prošvicová Jarmila ¹; Grim Jiří ²; Kopecký Jindřich ²; Priester Peter ²; Priester Iva ²; Trojanová Petronela ²; Jílková Věra ²; Paulík Adam ²; Lukešová Šárka ¹; Stanislav. Filip ²
Authors place of work: Oddělení klinické onkologie, Oblastní nemocnice Náchod a. s. ¹; Klinika onkologie a radioterapie FN Hradec Králové ²
Published in the journal: Klin Onkol 2018; 31(5): 361-365
Category: Original Articles
doi: https://doi.org/10.14735/amko2018361

Summary

Background:

Authors describe the incidence and character of neurologic and neuropsychiatric complications – particularly depression and parkinsonism – during adjuvant treatment of malignant melanoma (MM) with high dose interferon (HDI). Among the most frequently observed side effects are fatigue, hematotoxicity, and hepatotoxicity. Most research has been directed at depression and parkinsonism because of the lack of literature concerning these complications. Interferon induced parkinsonism has only been described rarely and only in case reports.

Patients and methods:

Twenty-nine patients with MM, treated from January 2010 to January 2014 with adjuvant high dose interferon alfa-2b intravenous (HDI 20MIU/sqm for 5 days per week during the first 4 weeks, and then maintenance subcutaneous 10MIU/sqm up to a total time of 1 year) were retrospectively evaluated and the incidence and character of neurologic and neuropsychiatric complications were determined.

Results:

Significant neurologic and neuropsychiatric complications were observed in 3 of the 29 patients. Dose modifications were required in 2 cases. One case developed parkinsonism and treatment had to be stopped after 10 applications of intravenous interferon.

Conclusion:

High dose interferon can cause depression and parkinsonism. Prophylaxis with antidepressant medication can keep the incidence of depression as low as 10% or lower. Development of parkinsonism during HDI is rare. According to available reports, this is the first description of parkinsonism development related to HDI in MM.

Key words

malignant melanoma – high dose interferon – neurologic and neuropsychiatric complication – drug-induced depression – drug-induced parkinsonism

The authors declare they have no potential conflicts of interest concerning drugs, products, or services used in the study.

The Editorial Board declares that the manuscript met the ICMJE recommendation for biomedical papers.

Submitted: 7. 4. 2018

Accepted: 16. 8. 2018

Zdroje

1. Basu B, Biswas S, Wrigley J et al. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategie. Expert Rev Anticancer Ther 2009; 9 (11): 1583–1598. doi: 10.1586/era.09.135.

2. Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med 2014; 370 (7): 663–664. doi: 10.1056/NEJMe1313690.

3. Kirkwood JM, Ibrahim J, Lawson DH et al. High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 2001; 19 (5): 1430–1436. doi: 10.1200/JCO.2001.19.5.1430.

4. Prošvicová (Vaňásková) J, Grim J, Kopecký J et al. High-dose interferon alfa v léčbě pacientů s maligním melanomem, sledování prediktivních a prognostických biomarkerů. Klin Onkol 2011; 24 (3): 180–186. doi: 10.14735/amko2011180.

5. Hauschild A, Gogas H, Tarhini A et al. Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer 2008; 112 (5): 982–994. doi: 10.1002/cncr.23251.

6. Trask PC, Paterson AG, Esper P et al. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004; 13 (8): 526–536. doi: 10.1002/pon.770.

7. Nishihori T, Abdo-Matkiwsky M, Fleishman SB et al. Severe action tremor related to interferon-alpha-2b therapy for malignant melanoma. Am J Clin Oncol 2005; 28: 526.

8. Greenberg DB, Jonasch E, Gadd MA et al. Adjuvant therapy of melanoma with interferon-alpha-2b is associated with mania and bipolar syndromes. Cancer 2000; 89 (2): 356–362.

9. Morgan JC, Sethi KD. Drug-induced tremors. Lancet Neurol 2005; 4 (12): 866–876. doi: 10.1016/S1474-4422 (05) 70250-7.

10. Kirkwood JM, Bender C, Agarwala S et al. Mecha-nisms and management of toxicities associated with high-doseinterferon alfa-2b therapy. J Clin Oncol 2002; 20 (17): 3703–3718. doi: 10.1200/JCO.2002.03.052.

11. Afzal MZ, Pinnamaneni V, Birendra KC et al. A retrospective analysis of tolerance and outcomes of cutaneous malignant melanoma in patients receiving adjuvant interferon-alpha-2b: a community oncology perspective. J Exp Ther Oncol 2017; 11 (2): 91–96.

12. Höschl C. Neurobiologie deprese. [online]. Dostupné z: http: //www.hoschl.cz/files/4841_cz_Hoschl_Neurobiologie%20deprese-CTS%202013.pdf.

13. Udina M, Moreno-España J, Capuron L et al. Cytokineinduced depression: current status and novel targets for depression therapy. CNS Neurol Disord Drug Targets 2014; 13 (6): 1066–1074.

14. Bonaccorso S, Puzella A, Marino V et al. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res 2001; 105 (1–2): 45–55.

15. Lieb K, Engelbrecht MA, Gut O et al. Cognitive impairment in patients with chronic hepatitis treated with interferon alpha (IFNalpha): results from a prospective study. Eur Psychiatry 2006; 21 (3): 204–210. doi: 10.1016/j.eurpsy.2004.09.030.

16. Zheng LS, Hitoshi S, Kaneko N et al. Mechanisms for interferon-α-induced depression and neural stem cell dysfunction. Stem Cell Reports 2014; 3 (1): 73–84. doi: 10.1016/j.stemcr.2014.05.015.

17. Musselman DL, Lawson DH, Gumnick JF et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001; 344 (13): 961–966. doi: 10.1056/NEJM200103293441303.

18. Valentine AD, Meyers CA, Kling MA et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol 1998; 25 (Suppl 1): 39–47.

19. Brigo F, Erro R, Marangi A et al. Differentiating drug-induced parkinsonism from Parkinson‘s disease: an update on non-motor symptoms and investigations. Parkinsonism Relat Disord 2014; 20 (8): 808–814. doi: 10.1016/ j.parkreldis.2014.05.011.

20. Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73 (4): 207–215. doi: 10.1159/000077739.

21. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma: a pilot study of exercise and methylphenidate. Oncol Nurs Forum 2002; 29 (7): E85–E90. doi: 10.1188/02.ONF.E85-E90.

22. Hanna TP, Baetz T, Xu J et al. Mental health services use by melanoma patients receiving adjuvant interferon: association of pre-treatment mental health care with early discontinuation. Curr Oncol 2017; 24 (6): e503–e512. doi: 10.3747/co.24.3685.

23. Okereke OI. Neuropsychiatric complications associated with interferon-alpha-2b treatment of malignant melanoma. Psychosomatics 2002; 43 (3): 237–240. doi: 10.1176/appi.psy.43.3.237.

24. Eggermont AM, Suciu S, MacKie R et al. Post-surgery adjuvant therapy with intermediat doses of interferon-alfa-2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial. Lancet 2005; 366 (9492): 1189–1196. doi: 10.1016/S0140-6736 (05) 67482-X.

25. Raison CL, Demetrashvili M, Capuron L et al. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005; 19 (2): 105–123.

26. Lohmann CP, Kroher G, Bogenrieder T et al. Severe loss of vision during adjuvant interferon-alfa-2b treatment for malignant melanoma. Lancet 1999; 353 (9161): 1326. doi: 10.1016/S0140-6736 (99) 00403-1.

27. Hejny C, Sternberg P, Lawson DH et al. Retinopathy associated with high-dose interferon-alfa-2b therapy. Am J Ophthalmol 2001; 131 (6): 782–787.

28. Loftis JM, Hauser P. Safety of the treatment of interferon-alpha-induced depression. Psychosomatics 2003; 44 (6): 524–526. doi: 10.1176/appi.psy.44.6.524.

29. Almeida CM, Galvão Mde L, Ferreira PL et al. Interferon-induced Parkinsonism in a patient with chronic hepatitis C. Arq Neuropsiquiatr 2009; 67 (3A): 715–716.

30. Wangensteen KJ, Boyd JT, Hamill RW et al. Interferon alpha treatment, hepatitis C and Parkinson‘s disease [abstract]. Movement Disorders 2013; 28 (Suppl 1): 828.

31. Bohlega SA, Al-Foghom NB. Drug-induced Parkinson‘s disease. A clinical review. Neurosciences (Riyadh) 2013; 18 (3): 215–221.